PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) Files An 8-K Other Events
Item 8.01. Other Events.

Protagonist Therapeutics, Inc. (the “Company”) is filing this Current Report on Form 8-K to correct the address for the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”) previously noted in the Company’s notice of Annual Meeting and definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 24, 2017 (the “Proxy Statement”). The correct address for the Annual Meeting is as follows:

Pacific Research Center

Conference Center

7677 Gateway Blvd.

Newark, CA 94560

The Annual Meeting will be held on May 25, 2017 at 10:00 a.m. local time. Directions to the Annual Meeting can be found on the Company’s website at www.protagonist-inc.com. Other information regarding the Annual Meeting and matters to be voted on can be found in the Proxy Statement.

About PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX)

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) Recent Trading Information

PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) closed its last trading session down -0.15 at 10.44 with 7,649 shares trading hands.